Table 1.

Findings of the systematic literature review on treatment options for enthesitis

DiseaseTested drug vs ReferenceSuperiority of the treatment arm against reference arm (p<0.05)Reference
PsATNFi vs PBOYESNCT00051623 (IFX)
NCT00265096 (GOL)
NCT01087788 (CZP)
TNFi+MTX vs PBO+MTX
(PBO+ETN one study) vs PBO+MTX
NONCT00367237 (IFX)
NCT02065713 (GOL)
NCT02376790 (ETN)
UST vs PBOYESNCT01009086
NCT01077362
UST vs TNFiYESEudraCT 2017-003799-29 β
GUS q4w vs PBO
GUS q8w vs PBO
YES
NO
NCT03162796
NCT03158285
SEC (pooled dose) vs PBOYESNCT01392326
NCT01752634
SEC 300mg vs PBO
SEC 150mg vs PBO
YES
NO
NCT01989468
SEC 300mg with loading vs PBO
SEC 150mg with loading vs PBO
SEC 150mg no loading vs PBO
YES
YES
NO
NCT02404350
IXE vs PBO
ADA vs PBO
YES
NO
PsA Bionaive
NCT01695239
IXE vs PBONO
PsA Bioexperienced
NCT02349295
IL17i (SEC/ ADA) vs TNFiNONCT02745080 (SEC)
NCT03151551 (ADA) β
APR 20mg vs PBO
APR 30mg vs PBO
NO
YES
NCT01172938
TOF 5mg vs PBO
TOF 10mg vs PBO
ADA 40mg vs PBO
NO
YES
NO
NCT01877668 (TNFi-naive)
TOF vs PBONONCT01882439 (TNFi-failure)
SpAETN vs SSZYES (imaging)/ NO (clinical)
axSpA
NCT00844142
ETN vs PBOYES for nr-axSpANCT01258738
ADA vs PBOYES for r-axSpA
NO for nr-axSpA
YES for perSpA
NCT00195819
NCT00939003
NCT01064856
GOL IV vs PBOYES for r-axSpANCT02186873
GOL 100mg vs PBO
GOL 50mg vs PBO
YES
NO
For r-axSpA
NCT00265083
GOL vs PBOYES nr-axSpANCT01453725
  • β-Open-label; PsA: Psoriatic arthritis; r-axSpA: Radiologic axial spondylarthritis; nr-axialSpA: non radiological axial spondylarthritis; PBO: Placebo; TNFi: Tumor necrosis factor inhibitors; ETN: Etanercept; IFX: Infliximab; ADA: Adalimumab; GOL: Golimumab; UST: Ustekinumab; CZP: Certolizmab; GUS: Guselkumab; SEC: Secukinumab; IXE: Ixekizumab; APR: Apremilast; TOF: Tofacitinib; MTX - Methotrexate